REG - Polarean Imaging PLC - Block listing application

Polarean ImagingAnnouncement

23/07/2021 09:30

RNS Number : 2827G
  
Polarean Imaging PLC
  
23 July 2021
  
 

Polarean Imaging Plc 
("Polarean" or the "Company")
 
Block listing application
 
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with an investigational proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that the Group has made an application to the London Stock Exchange for a block listing of 8,000,000 new ordinary shares of £0.00037 each in the capital of the Company in the capital of the Company ("Ordinary Shares") to be admitted to trading on AIM.
 
The Ordinary Shares will be issued from time to time pursuant to the Group's existing share plans including outstanding options already issued but not yet exercised to employees of the Group.
 
When issued, the Ordinary Shares under this block listing will rank pari passu with the Company's existing issued Ordinary Shares. It is expected that admission will be effective on or around 29 July 2021.
 
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
 
Enquiries:



Polarean Imaging plc


www.polarean.com / www.polarean-ir.com




Richard Hullihen, Chief Executive Officer


Via Walbrook PR




Jonathan Allis, Chairman








 








Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)


+44 (0)20 7710 7600




Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)








Nick Adams / Fred Walsh (Corporate Broking)


















Walbrook PR


Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com




Paul McManus / Anna Dunphy


Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001










 
 
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. 
 
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 
 
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. In December 2020, the Group received confirmation of acceptance of its NDA by the FDA, with a target PDUFA action date of 5 October 2021.
 
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
ALSGIGDRLDDDGBX